Angioedema in the Emergency Department: a Practical Guide to Differential Diagnosis and Management

Overview

Journal Int J Emerg Med

Publisher Biomed Central

Specialty Emergency Medicine

Date 2017 Apr 14

PMID 28405953

Citations 53

Authors

Jonathan A Bernstein

Paolo Cremonesi

Thomas K Hoffmann

John Hollingsworth

Affiliations

Soon will be listed here.

Abstract

Background: Angioedema is a common presentation in the emergency department (ED). Airway angioedema can be fatal; therefore, prompt diagnosis and correct treatment are vital.

Objective Of The Review: Based on the findings of two expert panels attended by international experts in angioedema and emergency medicine, this review aims to provide practical guidance on the diagnosis, differentiation, and management of histamine- and bradykinin-mediated angioedema in the ED.

Review: The most common pathophysiology underlying angioedema is mediated by histamine; however, ED staff must be alert for the less common bradykinin-mediated forms of angioedema. Crucially, bradykinin-mediated angioedema does not respond to the same treatment as histamine-mediated angioedema. Bradykinin-mediated angioedema can result from many causes, including hereditary defects in C1 esterase inhibitor (C1-INH), side effects of angiotensin-converting enzyme inhibitors (ACEis), or acquired deficiency in C1-INH. The increased use of ACEis in recent decades has resulted in more frequent encounters with ACEi-induced angioedema in the ED; however, surveys have shown that many ED staff may not know how to recognize or manage bradykinin-mediated angioedema, and hospitals may not have specific medications or protocols in place.

Conclusion: ED physicians must be aware of the different pathophysiologic pathways that lead to angioedema in order to efficiently and effectively manage these potentially fatal conditions.

Citing Articles

Deaths from Angioedema-Anaphylaxis and Covid-19.

Gray A, Ou R, Djabourian R, Augustine J, Sathyavagiswaran L Acad Forensic Pathol. 2025; :19253621251320212.

PMID: 39991143 PMC: 11843567. DOI: 10.1177/19253621251320212.

Management of acute ischemic stroke in the emergency department: optimizing the brain.

Ganti L Int J Emerg Med. 2025; 18(1):7.

PMID: 39773368 PMC: 11708089. DOI: 10.1186/s12245-024-00780-5.

The dynamics of thrombolysis over time in acute immunologic reactions.

Kienbacher C, Schorgenhofer C, Ruzicka G, Grafeneder J, Hufnagl C, Jilma B Sci Rep. 2025; 15(1):123.

PMID: 39747939 PMC: 11695695. DOI: 10.1038/s41598-024-84070-3.

A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System.

Ritter A, Silva S, de Paula R, Senra J, Carvalho F, Ribeiro T Front Med (Lausanne). 2024; 11:1343547.

PMID: 39309672 PMC: 11414478. DOI: 10.3389/fmed.2024.1343547.

Substance Use Disorder as Risk Factor for Intubation in Angioedema: A Nationwide Cohort Study.

Bogart J, Otteson T Laryngoscope. 2024; 135(1):45-49.

PMID: 39007365 PMC: 11635145. DOI: 10.1002/lary.31644.

References

Jalaj S, Scolapio J . Gastrointestinal manifestations, diagnosis, and management of hereditary angioedema. J Clin Gastroenterol. 2013; 47(10):817-23. DOI: 10.1097/MCG.0b013e31829e7edf. View

Bernstein J, Moellman J . Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. 2012; 5(1):39. PMC: 3518251. DOI: 10.1186/1865-1380-5-39. View

Lang D, Aberer W, Bernstein J, Chng H, Grumach A, Hide M . International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol. 2012; 109(6):395-402. DOI: 10.1016/j.anai.2012.10.008. View

Nosbaum A, Bouillet L, Floccard B, Javaud N, Launay D, Boccon-Gibod I . [Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema]. Rev Med Interne. 2013; 34(4):209-13. DOI: 10.1016/j.revmed.2012.12.017. View

Lin R, Levine R, Lin H . Adverse drug effects and angioedema hospitalizations in the United States from 2000 to 2009. Allergy Asthma Proc. 2013; 34(1):65-71. DOI: 10.2500/aap.2013.34.3618. View

Strom B, Carson J, Morse M, West S, Soper K . The effect of indication on hypersensitivity reactions associated with zomepirac sodium and other nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1987; 30(10):1142-8. DOI: 10.1002/art.1780301009. View

Williams-Johnson J, Hemmings S, Williams E, Channer G, McDonald A . Six years experience of angioedema at the University Hospital of the West Indies. West Indian Med J. 2007; 56(3):278-81. DOI: 10.1590/s0043-31442007000300018. View

Craig T, Levy R, Wasserman R, Bewtra A, Hurewitz D, Obtulowicz K . Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009; 124(4):801-8. DOI: 10.1016/j.jaci.2009.07.017. View

Zilberberg M, Jacobsen T, Tillotson G . The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010; 31(6):511-9. DOI: 10.2500/aap.2010.31.3403. View

10.

Miller D, Oliveria S, Berlowitz D, Fincke B, Stang P, Lillienfeld D . Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008; 51(6):1624-30. DOI: 10.1161/HYPERTENSIONAHA.108.110270. View

11.

Zuraw B, Bernstein J, Lang D, Craig T, Dreyfus D, Hsieh F . A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013; 131(6):1491-3. DOI: 10.1016/j.jaci.2013.03.034. View

12.

SETTIPANE G . Aspirin and allergic diseases: a review. Am J Med. 1983; 74(6A):102-9. DOI: 10.1016/0002-9343(83)90537-5. View

13.

Cruz M . Conestat alfa (ruconest): first recombinant c1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema. P T. 2015; 40(2):109-14. PMC: 4315111. View

14.

Caballero T, Baeza M, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C . Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011; 21(6):422-41. View

15.

Brown N, Ray W, Snowden M, Griffin M . Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996; 60(1):8-13. DOI: 10.1016/S0009-9236(96)90161-7. View

16.

Beavers C, Dunn S, Macaulay T . The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother. 2011; 45(4):520-4. DOI: 10.1345/aph.1P630. View

17.

Bernstein J, Moellman J, Collins S, Hart K, Lindsell C . Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol. 2015; 114(3):245-9. DOI: 10.1016/j.anai.2014.12.007. View

18.

Riedl M, Campion M, Horn P, Pullman W . Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2010; 105(6):430-436.e2. DOI: 10.1016/j.anai.2010.09.005. View

19.

Jaiganesh T, Hughan C, Webster A, Bethune C . Hereditary angioedema: a survey of UK emergency departments and recommendations for management. Eur J Emerg Med. 2011; 19(4):271-4. DOI: 10.1097/MEJ.0b013e32834c9e1f. View

20.

Bezalel S, Mahlab-Guri K, Asher I, Werner B, Sthoeger Z . Angiotensin-converting enzyme inhibitor-induced angioedema. Am J Med. 2014; 128(2):120-5. DOI: 10.1016/j.amjmed.2014.07.011. View